Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.65, $0.03 better than the analyst estimate of $0.62. Revenue for the quarter came in at $383.3 million versus the consensus estimate of $381.73 million.

• Fourth Quarter 2018 Highlights
  • Reported revenue was $383.3 million, an increase of 4.0% over the prior year, while organic sales were higher by 4.4% over the prior year;
  • GAAP earnings per diluted share amounted to $0.29, compared to $0.56 in the prior year; fourth quarter adjusted earnings per diluted share amounted to $0.65, compared to $0.64 in the prior year;
• Full-year 2018 Highlights
  • Reported revenue was $1,472.4 million, an increase of 23.9% over the prior year, which represents the fifth consecutive year of double-digit growth in reported revenue; organic sales were higher by 4.3% over the prior year;
  • GAAP earnings per diluted share amounted to $0.72, a 12.2% decrease over the prior year; full-year adjusted earnings per diluted share amounted to $2.42, a 24.7% increase over the prior year, which represents the fifth consecutive year of double-digit growth in adjusted earnings per share;
• 2019 Company Guidance
  • The Company expects full-year 2019 reported revenue in the range of $1.515 billion to $1.525 billion, representing 3.5% growth at the midpoint; organic revenue growth, which excludes the effect of foreign currency, acquisitions, divestitures and discontinued products, is expected to be approximately 5%; and
  • The Company expects full-year GAAP earnings per diluted share to be in the range of $1.36 to $1.43, and full-year adjusted earnings per diluted share to be in the range of $2.65 to $2.72.

"We are pleased to report fourth quarter sales and adjusted earnings per share at the high end of our guidance range," said Peter Arduini, Integra's President and Chief Executive Officer. "In 2018, we completed much of the work associated with the integration of Codman and the expansion of our commercial organizations. We look forward to launching over ten new products in 2019 and leveraging our more focused sales channels to accelerate organic growth."

GUIDANCE:

Integra LifeSciences sees FY2019 EPS of $2.65-$2.72, versus the consensus of $2.65. Integra LifeSciences sees FY2019 revenue of $1.515-1.525 million, versus the consensus of $1.53 million.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.